These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results

Loading...Loading...Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion, according to data from Benzinga Pro."With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launch ...